

## **NOMAD BIOSCIENCE Completes Sale of Its Subsidiary Icon Genetics to DENKA, Japan**

**August 21, 2017**

NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has completed the sale announced on August 6, 2015 with DENKI KAGAKU KOGYO KABUSHIKI KAISHA, Tokyo, Japan (the new name DENKA, “DENKA”) regarding sale in two phases of all of the shares of Icon Genetics GmbH (“ICON”), NOMAD’s wholly owned subsidiary. The sale was completed on August 21, 2017. NOMAD has sold 51% of ICON’s shares to DENKA (first phase) in August 2015, as a result of which ICON has become a subsidiary of DENKA, and after two years of implementation of the first phase, DENKA has acquired the remaining 49% of ICON’s shares, resulting in ICON becoming a wholly owned subsidiary of DENKA. Based on the agreement with DENKA, after the sale, ICON will carry out research and development in the vaccines and diagnostic reagents business. ICON continues to operate from Halle, Germany.

As a result of the acquisition, DENKA is committed to developing norovirus vaccine and other vaccines which have never been produced by Denka Seiken and, in relation to seasonal influenza vaccines currently produced by Denka Seiken, creating a brand new production technology that could replace the traditional one.

NOMAD retains all intellectual property rights to biopharmaceuticals and biomaterials other than vaccines and diagnostics, and intends to continue development of new biopharmaceuticals, including biosimilar and ‘biobetter’ antibodies.

The total acquisition amount to be paid by DENKA is a maximum of EUR 75 million (approximately, JPY10 billion or US\$ 85 million).

**About NOMAD BIOSCIENCE GmbH.** NOMAD BIOSCIENCE GmbH, formed in 2009, is a plant biotechnology company developing transient expression systems, and will invest part of the proceeds for applications in a broad range of agricultural, anti-microbial and pharmaceutical products. The company is actively seeking corporate partners to help develop and commercialize its products. NOMAD is led by Prof. Dr. Yuri Gleba. Corporate offices are headquartered in Munich, Germany and the research division is located in Halle, Germany. NOMAD BIOSCIENCE GmbH has two subsidiary companies: Nambawan Biotech GmbH (Halle, Germany) and UAB Nomads (Vilnius, Lithuania).

Contact info: [gleba@nomadbioscience.com](mailto:gleba@nomadbioscience.com)